Artificial Intelligence and Medicines Security

Executive argument

AI can improve forecasting, dependency discovery, quality surveillance and scenario analysis when supported by reliable data and accountable judgement.

High-value applications

Priority uses include demand sensing, shortage prediction, supplier-network mapping, anomaly detection and simulation of policy options.

Governance requirements

Institutions need documented model purposes, validated data, human escalation, performance monitoring and clear accountability.

Conclusion

AI should augment medicines-security institutions, not substitute for them.

Evidence notes and limits

This perspective proposes an analytical framing; it does not report an empirical study, systematic review or validated measurement. The sources below provide policy context. MSI’s recommendations remain its own interpretation and do not imply source endorsement.

Selected references

• WHO (2021), Ethics and governance of artificial intelligence for health · accessed 13 October 2026

Authorship, interests and review

Institutional authorship: Medicines Security Institute. Enquiries and corrections are overseen by the Founder & Executive Director. Independent peer review is not claimed. This record has no verified publication-specific funding or conflict disclosure; readers may request clarification through the research office.

Read the expanded full working-paper manuscript (October 2026 draft) →

Version record

September 2026: introductory record. 13 October 2026: clarified publication type, aligned downloadable text, added source notes and review limits. Substantive research expansion will be separately dated and reviewed.